

**Preliminary scientific program of CEHC and CELD
Budapest, 23-25 June, 2016
(Agenda/timetable are preliminary!)**

23 June, 2016 AM

2nd MEETING OF CENTRAL EUROPEAN HEPATOLOGICAL COLLABORATION (CEHC)

(Open to all participants from Czech Republic, Hungary, Poland, Slovakia)

9:30-9:40 Opening remarks

9:40-12:00 Collaborative research initiatives. Protocol proposals.

Chairs: Bela Hunyady (Hungary) and Robert Flisiak (Poland)

- 9:40-10:00 Comparison of liver biopsy vs. elastography in staging liver fibrosis - Peter Jarčuška 15 min + 5 min discussion
- 10:00-10:20 Elastographic follow-up of patients treated with IFN-free versus IFN based regimens for HCV. Gabor Horvath (Hungary) 15 min + 5 min discussion
- 10:20-10:40 CAP in NAFLD/HCV. Krzysztof Tomaszewicz (Poland) 15 min + 5 min discussion
- 10:40-11:00 Long term efficacy after DAA based therapies. Robert Flisiak (Poland) 15 min + 5 min discussion
- 11:00-11:20 Collection of screening strategies and experience. Michael Makara (Hungary) 15 min + 5 min discussion
- 11:20-11:40 Long term follow-up of TVR/BOC containing triple regimens. Bela Hunyady (Hungary) 15 min + 5 min discussion
- 11:40-12:00 How to succeed in generating international disease registries? Peter Hegyi (Hungary) 15 min + 5 min discussion

12:00-13:00 Lunch break

23 June, 2016 PM-1

COST-EFFECTIVENESS IN LIVER DISORDERS (CELD) CONFERENCE

13:00-13:10 Opening of CELD

13:10-14:30 Methodology in health technology assessment

Chair: Imre Boncz (Hungary) and Gabor Horvath (Hungary)

- 13:10-13:40 Basic concepts of health technology assessment. Imre Boncz (Hungary)
- 13:40-14:10 Cost - effectiveness assessment in liver diseases therapy - role of health technology assessment. Guenka Petrova (Bulgaria)
- 14:10-14:30 Discussion

23 June, 2016 PM-2

14:30-15:20 Cost-effectiveness issues in liver cirrhosis and genetic disorders of the liver

Chair: Ferenc Szalay (Hungary)

- 14:30-14:50 Cost-effectiveness of terlipressin in the treatment of acute esophageal variceal bleeding. Tamas Szamosi (Hungary)
- 14:50-15:10 Financial aspects of management of Wilson's disease and hemochromatosis. Ferenc Szalay (Hungary)
- 15:10-15:20 Discussion

15:20-15:40 Coffee break

23 June, 2016 PM-3

15:40-16:50 Free papers

Chairs: Bela Hunyady (Hungary), Istvan Tornai (Hungary)

- 15:40-15:55 Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin treatment of hepatitis C genotype 1b infected patients after failure to previous first generation protease-inhibitor therapy. An interim analysis. Bela Hunyady (Hungary)
- 15:55-16:10 Prescribing in alcohol related liver disease- are we up to date with current guidelines? Tessa Hanley (UK)
- 16:10-16:25 Economic burden of hepatitis B and C viruses infection in different stages of disease: A retrospective medical records based study from Southern of Iran. Mohammadreza Fattahi (Iran)
- 16:25-16:40 The Impact of Methadone Treatment on HCV/HIV prevalence among IDUs in Ukraine. Serhii Soloviov Serhii Soloviov (Ukraine)
- 16:40-16:50 Discussion

24 June, 2016 AM-1

08:30-09:30 How to finance real health care innovation in lower income European countries?

Part 1. Chairs: Krzysztof Landa (Poland) and Zoltan Kalo (Hungary)

- 08:30-09:00 How to finance real health care innovation in lower income European countries? The Polish example of HCV therapies. Krzysztof Landa (Poland)
- 09:00-09:20 Reimbursement policies and achievements on the field of hepatology in Lithuania. Kristina Garuoliene (Lithuania)
- 09:20-09:40 Achievements in introduction of new HCV therapies in Hungary. Judit Bidlo (Hungary)
- 09:40-10:00 Importance of collaboration to find better solutions for the treatment of liver diseases. Vladimir Zah (Serbia)
- 10:00-10:20 Discussion

10:00-10:20 Coffee break

10:20-11:30 How to finance real health care innovation in lower income European countries?

Part 2. Chairs: Krzysztof Landa (Poland) and Zoltan Kalo (Hungary)

- 10:20- 10:40 Reimbursement of innovative therapies for liver diseases in Slovenia. Mitja Kos (Slovenia)
- 10:40-11:00 Cure & Control of HCV in Romania. Andrei Tarnea (Romania)
- 11:00-11:20 Patients' perspective on potential eradication of HCV in Central-Eastern Europe. Stanimir Hasurdjiev (Bulgaria)
- 11:20-11:30 Discussion

24 June, 2016 AM-2

11:30-12:30 AbbVie symposium 60 min

12:30-13:30 Lunch break

24 June, 2016 PM-1

13:30-15:20 Cost-effectiveness issues in hepatitis C

Chairs: Geoffrey Dusheiko (UK) and Mihaly Makara (Hungary)

- 13:30-14:00 Birth-cohort screening for HCV in Europe. Screening for HCV in acute IVD population and in HIV co-infected population. Jean-Michel Pawlotsky (France)

- 14:00-14:20 Risk-based screening versus other screening strategies for HCV - what is the optimal approach in Central-Eastern Europe? Mihály Makara (Hungary)
- 14:20-14:50 IFN-based/IFN-free treatment versus observation in CHC. Geoffrey Dusheiko (UK)
- 14:50-15:20 Cost-effectiveness issues in hepatitis C. Livio Garattini (Italy)
- 15:20-15:40 Discussion

15:40-16:10 Coffee break

24 June, 2016 PM-2

16:10-18:00 Specific liver-disease related cost-effectiveness issues

Chairs: Peter Ferenci (Austria) and Robert Flisiak (Poland)

- 16:10-16:40 Cost effectiveness analysis: who benefits: big pharma, payer or the patient? Peter Ferenci (Austria)
- 16:40-17:10 Surveillance for HCC in compensated or decompensated HBV cirrhosis. Robert Flisiak (Bialystok, Poland)
- 17:10-17:40 Surveillance for HCC in non-cirrhotic CHB on NA treatment. Vasily Isakov (Moscow, Russia)
- 17:40-18:00 Discussion

24 June, 2016 PM-3

17:10-18:10 Gilead symposium

25 June, 2016 AM-1

08:30-10:00 Cost-effectiveness issues in hepatitis B

Chairs: Cihan Yurdaydin (Turkey) and Gabor Horvath (Hungary)

- 08:30-09:00 Vaccination against HBV at birth versus at age 12. Vaccination against HBV in elderly people. Cihan Yurdaydin (Turkey)
- 09:00-09:20 Entecavir versus tenofovir in compensated or decompensated HBV cirrhosis. Gabor Horvath (Hungary)
- 09:20-09:40 IFN versus NA for HBV in non-cirrhotic patients. Krzysztof Tomasiwicz (Poland)
- 09:40-10:00 Annual versus six-monthly follow up of HBV-DNA during long term NA therapy. Istvan Tornai (Hungary)
- 10:00-10:20 Discussion

10:20-10:40 Coffee break

25 June, 2016 AM-2

10:40-12:40 Treatment of HCV in Central-Eastern-Southern Europe.

Chairs: Cihan Yurdaydin (Turkey) and Jean-Michel Pawlotzky (UK)

- 10:40-11:00 Treatment of hepatitis C in Slovenia. Mojca Matičič (Slovenia)
- 11:00-11:20 Real World Data in Treating HCV - Amethyst Cohort, Bulgaria. Krasimir Antonov (Bulgaria)
- 11:20-11:40 Real World Data from AMBER study. Robert Flisiak (Poland)
- 11:40-12:00 Real life data for patients with HCV in Romania. Anca Streinu Cerel (Romania)
- 12:00-12:20 The cost analysis of HCV treatment in Ukraine. Olha Zalis'ka (Ukraine)

12:40-13:00 Closing remarks